---
document_datetime: 2026-02-04 12:52:34
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/erleada-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: erleada-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.4694029
conversion_datetime: 2026-02-05 11:37:10.410131
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.12)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Erleada

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                           |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 15/01/2026                          |                                             | SmPC and PL                      | Section 4.8 of the SmPC has been being updated to |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000303988                     | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.8 of the SmPC in order to update the frequency of the existing ADR 'Lichenoid eruption' from 'not known' to 'uncommon', based on a cumulative safety review. The Package Leaflet is updated accordingly.                                                                                                                                    |            |     | change the frequency of 'lichenoid eruption' from unknown to common.   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000322283 | B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.a Up to 10-fold compared to the originally approved batch size - Accepted                                                                                                                                                                                                                                                                                                                                                                      | 12/01/2026 | N/A |                                                                        |
| Variation type IB / EMA/VR/0000294415 | This was an application for a group of variations. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes | 21/11/2025 | N/A |                                                                        |

<div style=\"page-break-after: always\"></div>

| place - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted |

<div style=\"page-break-after: always\"></div>

|                                       | Minor change in the manufacturing process of the active substance - Accepted B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Up to 10-fold increase compared to the originally approved batch size - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted   |            |     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000296035 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z - to provide an updated RMP to remove the Targeted Follow-Up Questionnaires (TFUQs) for fall, non- pathological fracture and seizure from the EU-RMP, in alignment with the PRAC conclusions from the PSUSA Procedure PSUSA/00010745/202502                                                                                       | 19/11/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | (EMA/PSUR/0000269021).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |           |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------|
| PSUR / EMA/PSUR/0000269021            | - - In view of available data on apalutamide and neutropenia as well as agranulocytosis from spontaneous cases with positive dechallenge and/or rechallenge and compatible time to onset, data from clinical trials and in the literature, and in view of a potential mechanism of action, a causal relationship between apalutamide and neutropenia as well as apalutamide and agranulocytosis is at least a reasonable possibility and the product information of apalutamide containing products should be amended accordingly. | 18/09/2025 | 21/11/2025 | SmPC and PL | Variation |
| Variation type IB / EMA/VR/0000279277 | This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process                                                           | 04/08/2025 | N/A        |             |           |

<div style=\"page-break-after: always\"></div>

| of the active substance - B.I.b.1.d Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test method - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test method - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test method - Accepted   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate /   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| of the active substance - B.I.b.1.z Other  changes - Accepted  B.I.b.2 Change in test procedure for active  substance or starting  material/reagent/intermediate used in the  manufacturing process of the active  substance - B.I.b.2.c Other changes to a test  procedure (including replacement or  addition) for a reagent, which does not have  a significant effect on the overall quality of  the active substance - Accepted  B.I.b.2 Change in test procedure for active  substance or starting  material/reagent/intermediate used in the  manufacturing process of the active  substance - B.I.b.2.c Other changes to a test  procedure (including replacement or  addition) for a reagent, which does not have  a significant effect on the overall quality of  the active substance - Accepted  B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.c Other changes to a test procedure (including replacement or addition) for a reagent, which does not have a significant effect on the overall quality of the active substance - Accepted   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.c Other changes to a test procedure (including replacement or addition) for a reagent, which does not have a significant effect on the overall quality of the active substance - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.c Other changes to a test procedure (including replacement or addition) for a reagent, which does not have a significant effect on the overall quality of the active substance - Accepted   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000269329 | This was an application for a group of variations. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.2 Changes in the manufacturing                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 08/07/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | Minor change in the manufacturing process of the active substance - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted   |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000264853 | B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 08/04/2025 | N/A |